Short‐term intermittent parathyroid hormone (1–34) administration increased angiogenesis and matrix metalloproteinase 9 in femora of mature and middle‐aged C57BL/6 mice

• Published in: Experimental physiology Vol. 105; no. 7; pp. 1159 - 1171
• Main Authors: Lee, Seungyong, Prisby, Rhonda D.
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01.07.2020
• Subjects: Angiogenesis; Blood vessels; Bone marrow; bone vascular density; Cancellous bone; Endothelial cells; Gelatinase B; Homing behavior; Localization; Matrix metalloproteinase; matrix metalloproteinase 9; Metalloproteinase; Metaphysis; Osteoid; Parathyroid; Parathyroid hormone; Smooth muscle; parathyroid hormone; angiogenesis; bone vascular density; matrix metalloproteinase 9
• ISSN: 0958-0670; 1469-445X
• DOI: 10.1113/EP087869

New Findings What is the central question of this study? We sought to assess the effects of intermittent parathyroid hormone (1–34) administration on bone angiogenesis, the redistribution of bone marrow blood vessels, and matrix metalloproteinase 9 as a function of advancing age in mice. What is the main finding and its importance? Short‐term (i.e. 10 days) intermittent parathyroid hormone (1–34) administration increased the number of small (≤29‐µm‐diameter) bone marrow blood vessels and augmented matrix metalloproteinase 9. These changes occurred before alterations in trabecular bone. Given the rapid response in bone angiogenesis, this investigation highlights the impact of intermittent parathyroid hormone (1–34) administration on the bone vascular network. Intermittent parathyroid hormone (PTH) administration augments bone, stimulates the production of matrix metalloproteinase 9 (Mmp9) and relocates bone marrow blood vessels closer to osteoid seams. Discrepancies exist, however, regarding bone angiogenesis. Given that Mmp9 participates in cellular homing and migration, it might aid in blood vessel relocation. We examined the influence of short‐term intermittent PTH administration on angiogenesis, Mmp9 secretion and the distance between blood vessels and bone. Mature (6‐ to 8‐month‐old) and middle‐aged (10‐ to 12‐month‐old) male and female C57BL/6 mice were divided into three groups: control (CON), and 5 (5dPTH) and 10 days (10dPTH) of intermittent PTH administration. Mice were given PBS (50 µl day−1) or PTH(1–34) (43 µg kg−1 day−1). Frontal sections (5 µm thick) of the right distal femoral metaphysis were triple‐immunolabelled to identify endothelial cells (anti‐CD31), vascular smooth muscle cells (anti‐αSMA) and Mmp9 (anti‐Mmp9). Vascular density, Mmp9 density, area and localization, and blood vessel distance from bone were analysed. Blood vessels were analysed according to diameter: 1–29, 30–100 and 101–200 µm. Trabecular bone microarchitecture and bone static and dynamic properties were assessed. No main effects of age were observed for any variable. The density of CD31‐labelled blood vessels 1–29 and 30–100 µm in diameter was higher (P < 0.05) and tended (P = 0.055) to be higher, respectively, in 10dPTH versus 5dPTH and CON. Mmp9 was augmented (P < 0.05) in 10dPTH versus the other groups. Mmp9 was closer (P < 0.05) to blood vessels 1–29 µm in diameter and furthest (P < 0.05) from bone. In conclusion, bone angiogenesis occurred by day 10 of intermittent PTH administration, coinciding with augmented Mmp9 secretion near the smallest blood vessels (1–29 µm in diameter).